Insmed shares rise on positive late-stage trial results for lung disease therapy

Insmed Incorporated (NASDAQ:INSM) shares jumped almost 8% in early trade on Monday after the company reported positive topline results from a Phase 3b study evaluating its lung disease therapy ARIKAYCE. The ENCORE trial assessed ARIKAYCE (amikacin liposome inhalation suspension) in combination with standard multidrug therapy versus placebo plus multidrug therapy in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection who had not previously received antibiotics.